Loading viewer...
investor_presentation
Format: PDF investor_presentation
Marinus Pharmaceuticals presents its ganaxolone development pipeline for seizure disorder treatments, including FDA-approved ZTALMY and ongoing clinical trials for CDKL5 deficiency disorder, refractory status epilepticus, and Lennox-Gastaut syndrome. The presentation outlines anticipated regulatory milestones, commercialization plans, and the mechanism of action for ganaxolone as a GABAA receptor modulator.
presentation
investor_presentation
19 Pages
Xooker LLC
UOB Group 2024 Investor Presentation
investor_presentationinvestor_presentation
53 Pages
United Overseas Bank Limited
Sky Wave Gin Investment Deck 2022
investor_presentationinvestor_presentation
29 Pages
Sky Wave Distilling Company Limited